EUVIMED · CrossrefZeitschrift
Liver Cancer International
ISSN 2642-3561 · Wiley
Neueste Artikel
Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients
Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma
Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib
Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study
Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma
Regorafenib therapy for hepatocellular carcinoma in a HIV‐1‐infected patient: A case report
Issue Information
Issue Information
Issue Information
Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma
Issue Information
T‐cell mediated responses against alpha‐foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival
Prognostic significance of hypoxic and metabolic gene profiling in hepatocellular carcinoma
Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma
Salivary metabolites are promising non‐invasive biomarkers of hepatocellular carcinoma and chronic liver disease
Issue Information
Cover Image
Issue Information
Issue Information
Issue Information
Focal nodular hyperplasia after systemic chemotherapy: Pathological features of a series of 15 cases
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
Mutations in circulating cell‐free tumour DNA: Predictors of survival in hepatocellular carcinoma
Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria
Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients
Treating patients with advanced hepatocellular carcinoma and impaired liver function: Broadening the reach of anti‐cancer therapy
Unmet needs in basic and translational research in Cholangiocarcinoma
Endoscopic considerations for the management of cholangiocarcinoma
Multicentre external validation of the GES score for predicting HCC risk in Japanese HCV patients who achieved SVR following DAAs
Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?
EUVIMED